TY - JOUR
T1 - Quantification of free plasma DNA before and after chemotherapy in patients with advanced epithelial ovarian cancer
AU - Capizzi, Elisa
AU - Gabusi, Elena
AU - Grigioni, Antonia Derrico
AU - De Iaco, Pierandrea
AU - Rosati, Marta
AU - Zamagni, Claudio
AU - Fiorentino, Michelangelo
PY - 2008/3
Y1 - 2008/3
N2 - OBJECTIVES: A nonrandomized trial was planned to investigate the role of free plasma DNA (FPDNA) in patients with epithelial ovarian cancer before and after chemotherapy. Twenty-two patients with advanced stage ovarian cancer not suitable for debulking were treated with a neoadjuvant platinum/taxanes chemotherapy. Patients with clinical complete or partial response underwent radical hystero-oophorectomy, omentectomy, and lymphadenectomy and were followed up every 3 to 6 months. METHODS: Blood samples were obtained from each patient before chemotherapy, before each cycle, before and after surgery. FPDNA was quantified by real-time quantitative polymerase chain reaction using the Quantifiler Human Quantification Kit and expressed in ng/mL. Fifty female healthy blood donor volunteers were used as controls. RESULTS: Median FPDNA quantities discriminated between patients before chemotherapy (29.6±22.7mL) and controls (6.4±4. /mL) using a 14.5mL cutoff with 77% sensitivity and 96% specificity (P
AB - OBJECTIVES: A nonrandomized trial was planned to investigate the role of free plasma DNA (FPDNA) in patients with epithelial ovarian cancer before and after chemotherapy. Twenty-two patients with advanced stage ovarian cancer not suitable for debulking were treated with a neoadjuvant platinum/taxanes chemotherapy. Patients with clinical complete or partial response underwent radical hystero-oophorectomy, omentectomy, and lymphadenectomy and were followed up every 3 to 6 months. METHODS: Blood samples were obtained from each patient before chemotherapy, before each cycle, before and after surgery. FPDNA was quantified by real-time quantitative polymerase chain reaction using the Quantifiler Human Quantification Kit and expressed in ng/mL. Fifty female healthy blood donor volunteers were used as controls. RESULTS: Median FPDNA quantities discriminated between patients before chemotherapy (29.6±22.7mL) and controls (6.4±4. /mL) using a 14.5mL cutoff with 77% sensitivity and 96% specificity (P
KW - CA-125
KW - Chemotherapy
KW - Epithelial ovarian cancer
KW - Free plasma DNA
KW - Molecular pathology
UR - http://www.scopus.com/inward/record.url?scp=41749111607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41749111607&partnerID=8YFLogxK
U2 - 10.1097/PDM.0b013e3181359e1f
DO - 10.1097/PDM.0b013e3181359e1f
M3 - Article
C2 - 18303408
AN - SCOPUS:41749111607
VL - 17
SP - 34
EP - 38
JO - Diagnostic Molecular Pathology
JF - Diagnostic Molecular Pathology
SN - 1052-9551
IS - 1
ER -